Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Current Research Studies

Guanfacine for Hyperactivity in Children with Down Syndrome

HYPEbeGONE_DS

Phase: II
Clinicaltrials.gov ID: NCT06042257

What is the goal of the study?

1. Determine efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention in children with Down syndrome after 8 weeks of treatment. 2. Characterize the safety of guanfacine immediate release in children with Down syndrome

Who can participate in the study?

Children ages 6-12 years old with Down syndrome and hyperactivity/ADHD

Study Team:

PI (Study Doctor): Julia Mattson
Study Team Member: Alyssa Taira, [email protected]